Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications

被引:14
|
作者
Choi, Su-Yeon [2 ]
Park, Hyo Eun [2 ]
Kim, Min-Kyung [2 ]
Shin, Chan Soo [2 ]
Cho, Sang-Heon [2 ]
Oh, Byung-Hee [1 ]
机构
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Healthcare Syst Gangnam Ctr, Seoul 135984, South Korea
关键词
Low-density lipoprotein cholesterol; Friedewald formula; Diabetes mellitus; Triglyceride; Community-based study; CORONARY-HEART-DISEASE; ASSAY; RISK;
D O I
10.1016/j.jacl.2011.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: We evaluated factors that caused differences between calculated low-density lipoprotein cholesterol (C-LDL-C) and direct-measured LDL-C (D-LDL-C) and compared them in subjects with diabetes mellitus (DM) or taking lipid-lowering medications. METHODS: 21,452 subjects (9,177 women, 12,275 men; 8.1% with DM and 8.5% on lipid-lowering medications) were included in the analysis. Participants were classified into 3 groups, i.e., group 1: the subjects without DM and not on lipid-modifying drugs (n = 18,287), group 2: without DM and on lipid-modifying drugs (n = 1,423), and group 3: with DM (n = 1,742). LDL-C concentrations were either directly measured by a homogenous method or calculated by Friedewald formula. RESULTS: There was a significant correlation between C-LDL-C and D-LDL-C (r = 0.966, P < .001). The absolute values of the differences between two LDL-C values were 7.0 +/- 6.2 mg/dl and 6.6 +/- 7.3% (6.6 +/- 5.9 mg/dl and 6.0 +/- 6.5%, 8.8 +/- 6.7 mg/dl and 9.1 +/- 9.7%, and 10.1 +/- 7.3 mg/dl and 10.7 +/- 10.1% in group 1, 2, and 3 respectively, P < .001). The subjects with the absolute value of the differences of LDL-C >= 10% was 20.2% (17.3%, 31.3%, and 41.1% in group 1, 2, and 3 respectively, P < .001). In the multiple logistic regression analysis, high triglyceride (>= 150 mg/dl), low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dl), male gender, obesity (body mass index >= 25 kg/m(2)), DM and taking lipid-lowering drugs were significant associated with high LDL-differences (the absolute value of the differences >= 10% or >= 10 mg/dl). CONCLUSION: D-LDL-C was generally higher by 5 mg/dl or 5% than C-LDL-C. The differences C-LDL-C and D-LDL-C were higher in subjects with DM and on lipid-lowering medications. Male gender, high triglyceride, low HDL-C, and obesity were also associated with the greater differences between C-LDL-C and D-LDL-C. (C) 2012 National Lipid Association. All rights reserved.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 50 条
  • [1] Association between measured or calculated small dense low-density lipoprotein cholesterol and oxidized low-density lipoprotein in subjects with or without type 2 diabetes mellitus
    Kim, Hyun-Ki
    Hong, Jinyoung
    Ahn, Sunyoung
    Lee, Woochang
    Chun, Sail
    Min, Won-Ki
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2023, 37 (01)
  • [2] Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy
    Takaeko, Yuji
    Kajikawa, Masato
    Kishimoto, Shinji
    Yamaji, Takayuki
    Harada, Takahiro
    Han, Yiming
    Kihara, Yasuki
    Hida, Eisuke
    Chayama, Kazuaki
    Goto, Chikara
    Aibara, Yoshiki
    Yusoff, Farina Mohamad
    Maruhashi, Tatsuya
    Nakashima, Ayumu
    Higashi, Yukihito
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 15
  • [3] Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Khan, Safi U.
    Rahman, Hammad
    Okunrintemi, Victor
    Riaz, Haris
    Khan, Muhammad Shahzeb
    Sattur, Sudhakar
    Kaluski, Edo
    Lincoff, A. Michael
    Martin, Seth S.
    Blaha, Michael J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (07):
  • [4] An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals
    Buonvino, Camille
    Chopard, Romain
    Guillon, Benoit
    Puymirat, Etienne
    Farnier, Michel
    Ferrieres, Jean
    Krempf, Michel
    Bruckert, Eric
    Meneveau, Nicolas
    Schiele, Francois
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2020, 9 (08) : 879 - 887
  • [5] Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
    Abdalwahab, Ahmed
    Al-Atta, Ayman
    Zaman, Azfar
    Alkhalil, Mohammad
    WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (09): : 472 - 482
  • [6] Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome:: Impact on lipid-lowering therapy?
    Kronenberg, F
    Lingenhel, A
    Lhotta, K
    Rantner, B
    Kronenberg, MF
    König, P
    Thiery, J
    Koch, M
    von Eckardstein, A
    Dieplinger, H
    KIDNEY INTERNATIONAL, 2004, 66 (01) : 348 - 354
  • [7] Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
    Bays, Harold E.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2014, 7 : 355 - 364
  • [8] Equation-Based Low-Density Lipoprotein Cholesterol Reclassification and Implications For Lipid-Lowering Therapy
    Zheutlin, Alexander R.
    Niforatos, Joshua D.
    Chaitoff, Alexander
    MAYO CLINIC PROCEEDINGS, 2023, 98 (08) : 1258 - 1259
  • [9] Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy
    Giraldez, Roberto R.
    Giugliano, Robert P.
    Mohanavelu, Satishkumar
    Murphy, Sabina A.
    McCabe, Carolyn H.
    Cannon, Christopher P.
    Braunwald, Eugene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (11) : 914 - 920
  • [10] Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus
    Niemeijer-Kanters, SDJM
    Dallinga-Thie, GM
    de Ruijter-Heijstek, FC
    Algra, A
    Erkelens, DW
    Banga, JD
    Jansen, H
    ATHEROSCLEROSIS, 2001, 156 (01) : 209 - 216